In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!

Abstracts discussed:

• https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
• https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
• https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
• https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
• https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
• https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
• https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
• https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)

OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!

Abstracts Discussed!

1. SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html
2. Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html
3. BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html
4. CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study)
5. Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html
6. POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!

Abstracts:

• FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html
• Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html
• JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html
• SAVE Trial (Revumenib + PO Dec/ven): https://ash.confex.com/ash/2023/webprogram/Paper182337.html
• Dec/Ven vs. 3+7 Randomized Phase II: https://ash.confex.com/ash/2023/webprogram/Paper181347.html
• NCRI AML18 RCT: https://ash.confex.com/ash/2023/webprogram/Paper185956.html
• Impact of NPM1+/FLT3+/MRD in AML17 and AML19: https://ash.confex.com/ash/2023/webprogram/Paper179033.html
• CBF and NPM1 MRD: https://ash.confex.com/ash/2023/webprogram/Paper184848.html
• Persistent MRD by PCR but Flow Negativity in CBF AML (Mast Cell Madness): https://ash.confex.com/ash/2023/webprogram/Paper180275.html
• MORPHO More MRD Analysis: https://ash.confex.com/ash/2023/webprogram/Paper177929.html

In this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out!

Abstracts Discussed:

• https://ash.confex.com/ash/2023/webprogram/Paper188547.html
  
• https://ash.confex.com/ash/2023/webprogram/Paper181765.html
• https://ash.confex.com/ash/2023/webprogram/Paper177954.html
• https://ash.confex.com/ash/2023/webprogram/Paper191911.html
• https://ash.confex.com/ash/2023/webprogram/Paper179866.html
• https://ash.confex.com/ash/2023/webprogram/Paper177546.html
• https://ash.confex.com/ash/2023/webprogram/Paper178835.html
• Also check out Manni's excellent tweetorial on some of these key abstracts: https://x.com/ManniMD1/status/1726980328559133028?s=20

In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!

• Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/
• SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/
• Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/
• RADIUS (midostaurin): https://pubmed.ncbi.nlm.nih.gov/33288862/
• AMLSG 16-10 (midostaurin): https://pubmed.ncbi.nlm.nih.gov/30563875/
• MORPHO (EHA abstract): https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty.presenters.bmt-ctn.1506.28morpho29.a.randomized.trial.of.the.flt3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmorpho

In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study.

Key References:

• QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/
• QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/

• ASH Abstract Data on impact of # of Consolidation Cycles: https://ash.confex.com/ash/2020/webprogram/Paper138498.html
• Hovon 97 (Azacitidine SQ maintenance): https://pubmed.ncbi.nlm.nih.gov/30630862/

• Mayer, et al. NEJM. 1994. (CALGB HiDAC consolidation): https://pubmed.ncbi.nlm.nih.gov/8078551/
• Büchner, et al. JCO. 1985: https://pubmed.ncbi.nlm.nih.gov/3906048/

In this episode, we are joined by classical hematology experts, Madeleine Ochs, PharmD, BCOP and Justin Arnall, PharmD, BCOP, to teach us hemophilia 101!

In this T-Swift themed, episode, we discuss the history of hemophilia treatment (through the "eras") and how new agents may change the management of hemophilia patients.